RecruitingPHASE1, PHASE2NCT05906953
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
Studying Leber congenital amaurosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
- Principal Investigator
- Study DirectorHuidaGene Therapeutics Co., Ltd.
- Intervention
- HG004(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 6-50 years · All sexes
- Timeline
- 2023 – 2025
Study locations (3)
- Research Site, Sacramento, California, United States
- Research Site, Houston, Texas, United States
- Research Site, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05906953 on ClinicalTrials.govOther trials for Leber congenital amaurosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06891443Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)Laboratoires Thea
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06088992Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03920007Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2DAtsena Therapeutics Inc.
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03913143A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)ProQR Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT00999609Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisSpark Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01208389Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Spark Therapeutics, Inc.